Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Eukaryotic translation initiation factor 4E-binding protein 3 (EIF4EBP3) is a member of the EIF4EBP family that binds eukaryotic translation initiation factor 4E (EIF4E) and regulates its assembly into the eIF4F complex, thereby controlling cap-dependent translation initiation. This regulation occurs through competitive binding: when 4E-BP3 is hypo-phosphorylated, it binds strongly to EIF4E and represses translation; upon phosphorylation by mTOR signaling, it dissociates, enabling translation initiation. EIF4EBP3 also inhibits EIF4E-mediated nuclear mRNA export. Its biological role is closely linked to controlling protein synthesis rates, cellular growth, and potentially tumor suppression. Dysregulation or methylation-induced silencing of EIF4EBP3 has been associated with cancer progression[2][7][8][6].
Modulation of EIF4E activity by phosphorylation/dephosphorylation of EIF4EBP3 controls translation initiation rate; hypo-phosphorylated 4E-BP3 binds and inhibits EIF4E, repressing cap-dependent translation, whereas mTOR-mediated phosphorylation causes dissociation and allows translation initiation[8][2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Eukaryotic translation initiation factor 4E-binding protein 3 (EIF4EBP3).